HSPiP, computational, and thermodynamic models-based solubility validation of tofacitinib in PEG400 – water system, shelf-life estimation, and GastroPlus-enabled predictive in vivo performance
DARU Journal of Pharmaceutical Sciences · 03.11.2026 · 34 (2)
DOI: 10.1007/s40199-026-00674-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift DARU Journal of Pharmaceutical Sciences, online erschienen am 03.11.2026. Verfasst von Afzal Hussain und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, King Saud University, 11451, Riyadh, Saudi Arabia. amohammed2@ksu.edu.sa. Hauptthemen laut MEDLINE: Polyethylene Glycols, Pyrimidines, Piperidines. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The subcutaneous (sub-Q) delivery of tofacitinib citrate (TOFA) can be a promising alternative to overcome oral associated side effects and complications .
Objective
The study aimed to address HSPiP based predicted solubility and solubility behaviour of TOFA in various mass ratios ( m = 0.0–1.0) of PEG400 in PEG400-water system T = 298.15–318.15 K.
Methods
Hansen solubility parameters were estimated and the experimental solubility data were validated using various models (Van’t Hoff, Apelblat, Roseman-Yalkowsky, and thermodynamic models). Finally, the stability study was conducted to estimate TOFA shelf-life, followed by GastroPlus-based predictive in vivo performance in humans.
Results
PEG400 addition resulted in reduced δ_p and δ_h values up to m = 0.5, which may be correlated to the effective disruption of extensive H-bond network strength and decreased overall polarity of water by PEG400, as predicted in HSPiP. The temperature-dependent solubility was validated with the models. The binary system ( m = 0.5) exhibited stable solubility, suitable for sub-Q delivery. The enthalpy-entropy compensation temperature ( T _ c ) was 59.5 °C, suggesting constant Δ_sol G° over m = 0.1–0.9 of PEG400. Thus, TOFA solubility and stability were temperature, mass, and pH dependent. GastroPlus software predicted improved pharmacokinetic parameters and extended in vivo absorption following sub-Q delivery at m = 0.5 in humans.
Conclusion
Thus, a stable sub-Q product can be a promising alternative to the conventional tablet of TOFA. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, College of Pharmacy, King Saud University, 11451, Riyadh, Saudi Arabia. amohammed2@ksu.edu.sa.
- Department of Pharmaceutical Sciences, School of Pharmacy, The University of Texas at El Paso, El Paso, USA.
- School of Pharmacy, Sister Nivedita University, West Bengal, 700156, Kolkata, India.
- Department of Pharmaceutics, College of Pharmacy, King Saud University, 11451, Riyadh, Saudi Arabia.
- Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Reynolds Medical Sciences Building, TX, Texas A&M University, Suite 308, 77843, College Station, USA.
ORCID-Profile: Mohammad A Altamimi
Zitieren
APA
Hussain, A., Rafiq, Z., Ehsan, I., Altamimi, M. A., & Khuroo, T. (2026). HSPiP, computational, and thermodynamic models-based solubility validation of tofacitinib in PEG400 – water system, shelf-life estimation, and GastroPlus-enabled predictive in vivo performance. DARU Journal of Pharmaceutical Sciences, 34(2). https://doi.org/10.1007/s40199-026-00674-2
Vancouver
Hussain A, Rafiq Z, Ehsan I, Altamimi MA, Khuroo T. HSPiP, computational, and thermodynamic models-based solubility validation of tofacitinib in PEG400 – water system, shelf-life estimation, and GastroPlus-enabled predictive in vivo performance. DARU Journal of Pharmaceutical Sciences. 2026;34(2). doi:10.1007/s40199-026-00674-2
BibTeX
@article{Hussain2026,
author = {Hussain, Afzal and Rafiq, Zahid and Ehsan, Iman and Altamimi, Mohammad A and Khuroo, Tahir},
title = {HSPiP, computational, and thermodynamic models-based solubility validation of tofacitinib in PEG400 – water system, shelf-life estimation, and GastroPlus-enabled predictive in vivo performance},
journal = {DARU Journal of Pharmaceutical Sciences},
year = {2026},
volume = {34},
number = {2},
doi = {10.1007/s40199-026-00674-2}
}
EUVIMED